Literature DB >> 19906975

A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Jana K Shirey1, Ashley E Brady, Paulianda J Jones, Albert A Davis, Thomas M Bridges, J Phillip Kennedy, Satyawan B Jadhav, Usha N Menon, Zixiu Xiang, Mona L Watson, Edward P Christian, James J Doherty, Michael C Quirk, Dean H Snyder, James J Lah, Allan I Levey, Michelle M Nicolle, Craig W Lindsley, P Jeffrey Conn.   

Abstract

M(1) muscarinic acetylcholine receptors (mAChRs) may represent a viable target for treatment of disorders involving impaired cognitive function. However, a major limitation to testing this hypothesis has been a lack of highly selective ligands for individual mAChR subtypes. We now report the rigorous molecular characterization of a novel compound, benzylquinolone carboxylic acid (BQCA), which acts as a potent, highly selective positive allosteric modulator (PAM) of the rat M(1) receptor. This compound does not directly activate the receptor, but acts at an allosteric site to increase functional responses to orthosteric agonists. Radioligand binding studies revealed that BQCA increases M(1) receptor affinity for acetylcholine. We found that activation of the M(1) receptor by BQCA induces a robust inward current and increases spontaneous EPSCs in medial prefrontal cortex (mPFC) pyramidal cells, effects which are absent in acute slices from M(1) receptor knock-out mice. Furthermore, to determine the effect of BQCA on intact and functioning brain circuits, multiple single-unit recordings were obtained from the mPFC of rats that showed BQCA increases firing of mPFC pyramidal cells in vivo. BQCA also restored discrimination reversal learning in a transgenic mouse model of Alzheimer's disease and was found to regulate non-amyloidogenic APP processing in vitro, suggesting that M(1) receptor PAMs have the potential to provide both symptomatic and disease modifying effects in Alzheimer's disease patients. Together, these studies provide compelling evidence that M(1) receptor activation induces a dramatic excitation of PFC neurons and suggest that selectively activating the M(1) mAChR subtype may ameliorate impairments in cognitive function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906975      PMCID: PMC2811323          DOI: 10.1523/JNEUROSCI.3930-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

Review 1.  An integrative theory of prefrontal cortex function.

Authors:  E K Miller; J D Cohen
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Therapeutic opportunities for muscarinic receptors in the central nervous system.

Authors:  C C Felder; F P Bymaster; J Ward; N DeLapp
Journal:  J Med Chem       Date:  2000-11-16       Impact factor: 7.446

Review 3.  A new benzodiazepine pharmacology.

Authors:  H Möhler; J M Fritschy; U Rudolph
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

4.  Elucidating the role of muscarinic receptors in psychosis.

Authors:  C C Felder; A C Porter; T L Skillman; L Zhang; F P Bymaster; N M Nathanson; S E Hamilton; J Gomeza; J Wess; D L McKinzie
Journal:  Life Sci       Date:  2001-04-27       Impact factor: 5.037

Review 5.  On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

Authors:  R T Bartus
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

6.  Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord.

Authors:  V Morisset; L Urban
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

7.  Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor.

Authors:  T Miyakawa; M Yamada; A Duttaroy; J Wess
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

8.  Muscarinic-induced modulation of potassium conductances is unchanged in mouse hippocampal pyramidal cells that lack functional M1 receptors.

Authors:  S T Rouse; S E Hamilton; L T Potter; N M Nathanson; P J Conn
Journal:  Neurosci Lett       Date:  2000-01-07       Impact factor: 3.046

9.  Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.

Authors:  J L Cummings; A Nadel; D Masterman; P A Cyrus
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

10.  The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.

Authors:  R M Nitsch; M Deng; M Tennis; D Schoenfeld; J H Growdon
Journal:  Ann Neurol       Date:  2000-12       Impact factor: 10.422

View more
  97 in total

1.  Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

Authors:  Evan P Lebois; Gregory J Digby; Douglas J Sheffler; Bruce J Melancon; James C Tarr; Hyekyung P Cho; Nicole R Miller; Ryan Morrison; Thomas M Bridges; Zixiu Xiang; J Scott Daniels; Michael R Wood; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2011-08-24       Impact factor: 2.823

2.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

3.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

Review 4.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

5.  The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner.

Authors:  Benoit Poulin; Adrian Butcher; Phillip McWilliams; Julie-Myrtille Bourgognon; Robert Pawlak; Kok Choi Kong; Andrew Bottrill; Sharad Mistry; Jürgen Wess; Elizabeth M Rosethorne; Steven J Charlton; Andrew B Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 6.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

Review 7.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

8.  The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Authors:  Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Joseph D Panarese; James M Salovich; Kellie D Nance; Darren W Engers; Jerri M Rook; Anna L Blobaum; Colleen M Niswender; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-05-05       Impact factor: 2.823

9.  Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors.

Authors:  Lisa M Broad; Helen E Sanger; Adrian J Mogg; Ellen M Colvin; Ruud Zwart; David A Evans; Francesca Pasqui; Emanuele Sher; Graham N Wishart; Vanessa N Barth; Christian C Felder; Paul J Goldsmith
Journal:  Br J Pharmacol       Date:  2018-11-16       Impact factor: 8.739

10.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.